LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Input momentum (manajer yang sebanding):
keluasan pemegang +4.0% ·
aliran saham +0.6% ·
posisi baru bersih +3.8%
— formula
Akumulasi luas — peningkatan saham di lebih banyak pemegang
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q4 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasif) | 34.31M | — | $26.49B | 1.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 4 | Capital World Investors ✦ | 19.55M | -4.0% | $15.09B | 2.3% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasif) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasif) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 16.76M | -5.3% | $12.94B | 10.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 13 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 17 | Norges Bank ✦ (pasif) | 10.89M | +3.9% | $8.41B | 1.1% | ▲ Add | 3 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 5.24M | +3.5% | $4.04B | 1.6% | ▲ Add | 3 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 1.31M | +35.1% | $1.01B | 3.8% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 22 | Millennium Management ✦ | 801.07K | -19.1% | $618.42M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 23 | Lone Pine Capital ✦ | 782.86K | Baru | $604.37M | 4.5% | New | 1 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 732.55K | -11.7% | $565.53M | 1.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 33 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 34 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 35 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 36 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 37 | Two Sigma Investments ✦ | 322.69K | +61.6% | $249.12M | 0.6% | ▲ Add | 3 | SEC ↗ |
| 38 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 39 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 40 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 41 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 42 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 43 | Bridgewater Associates ✦ | 84.36K | +15.1% | $65.12M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 44 | Duquesne Family Office ✦ | 62.19K | Baru | $48.01M | 1.4% | New | 1 | SEC ↗ |
| 45 | Renaissance Technologies ✦ | 54.12K | -79.0% | $41.78M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 46 | Dodge & Cox ✦ | 44.80K | -0.7% | $34.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 47 | Soros Fund Management ✦ | 33.64K | Baru | $25.97M | 0.7% | New | 1 | SEC ↗ |
| 48 | GAMCO Investors ✦ | 33.54K | -3.6% | $25.90M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 49 | Arrowstreet Capital ✦ | 14.85K | -99.1% | $11.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 50 | Gotham Asset Management ✦ | 5.78K | -32.1% | $4.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Lone Pine Capital | $604.37M | 4.5% |
| Duquesne Family Office | $48.01M | 1.4% |
| Soros Fund Management | $25.97M | 0.7% |
Telah keluar
| Viking Global Investors | $134.70M | adalah 0.5% |
| Point72 Asset Management | $11.66M | adalah 0.0% |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 4,323 pemegang, 762.84M saham, $674.93B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Officer · 6.50K lbr · $7.64M
Officer · 2.00K lbr · $2.37M
Officer · 5.00K lbr · $5.95M
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters